Korkmaz, Selcuk (Trakya author)Background Although tests of global hemostasis prothrombin time (PT) and activated partial thromboplastin time (aPTT) should not be used for prediction of bleeding risk, these tests are often used by many clinicians in daily practice particularly as a preoperative screening test. Robust biological variation (BV) data are needed for safe clinical applications of these tests. In this study, a stringent protocol was followed to estimate the BV's for PT, aPTT, and fibrinogen levels. Methods Results Weekly blood samples were obtained from 28 healthy individuals (18 females, 10 males) during 10 weeks study period. All measurements were performed with Stago STA-R coagulation analyzer. Prior to coefficient of variatio...
BACKGROUND: CoaguChek XS is one of the most widely used point-of-care (POC) devices to evaluate prot...
OBJECTIVES: Biological variation (BV) data obtained in a standardized way is valuable to assess the ...
Background: Bleeding assessment tools are key screening tests used in the evaluation of patients wit...
Background: Differences in blood group have been associated with predisposition to some diseases. Ac...
The two components of biological variability are interindividual variability, which is the variabili...
Background: Concentrations of inflammatory and hemostatic variables are influenced by biological var...
Background For biological variation (BV) data to be safely used, data must be reliable and relevant ...
Background and objectives: ABO blood group distribution defers with racial and geographic variations...
Introduction: Prothrombin time (PT) and activated partial thromboplastin time (APTT) are important c...
textabstractHypofibrinolysis is a risk factor for venous and arterial thrombosis, and can be assesse...
BACKGROUND: Evaluation of an individual's thrombin-generating capacity enables a global assessment o...
Based on the premise that the capacity of plasma to generate thrombin in vitro is a comprehensive an...
Background: Coagulation, also known as blood clotting, is the process by which blood convert from a ...
Abstract Background For biological variation (BV...
The standard clinical coagulation assays, activated partial thromboplastin time (aPTT) and prothromb...
BACKGROUND: CoaguChek XS is one of the most widely used point-of-care (POC) devices to evaluate prot...
OBJECTIVES: Biological variation (BV) data obtained in a standardized way is valuable to assess the ...
Background: Bleeding assessment tools are key screening tests used in the evaluation of patients wit...
Background: Differences in blood group have been associated with predisposition to some diseases. Ac...
The two components of biological variability are interindividual variability, which is the variabili...
Background: Concentrations of inflammatory and hemostatic variables are influenced by biological var...
Background For biological variation (BV) data to be safely used, data must be reliable and relevant ...
Background and objectives: ABO blood group distribution defers with racial and geographic variations...
Introduction: Prothrombin time (PT) and activated partial thromboplastin time (APTT) are important c...
textabstractHypofibrinolysis is a risk factor for venous and arterial thrombosis, and can be assesse...
BACKGROUND: Evaluation of an individual's thrombin-generating capacity enables a global assessment o...
Based on the premise that the capacity of plasma to generate thrombin in vitro is a comprehensive an...
Background: Coagulation, also known as blood clotting, is the process by which blood convert from a ...
Abstract Background For biological variation (BV...
The standard clinical coagulation assays, activated partial thromboplastin time (aPTT) and prothromb...
BACKGROUND: CoaguChek XS is one of the most widely used point-of-care (POC) devices to evaluate prot...
OBJECTIVES: Biological variation (BV) data obtained in a standardized way is valuable to assess the ...
Background: Bleeding assessment tools are key screening tests used in the evaluation of patients wit...